Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06268665
Other study ID # UCDCC307
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date February 28, 2024
Est. completion date June 2027

Study information

Verified date February 2024
Source University of California, Davis
Contact Eve Rodler, MD
Phone 916-734-5959
Email erodler@ucdavis.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy. Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2).


Description:

PRIMARY OBJECTIVE: I. Efficacy of tart cherry juice supplementation in the prevention of paclitaxel-induced peripheral neuropathy (PIPN) in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy. SECONDARY OBJECTIVE: I. Compare the effectiveness of high- dose and low-dose tart cherry juice supplement in reducing the severity of PIPN in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy. II. Assess the impact of tart cherry juice on dose delivery of taxane chemotherapy. III. Ascertain the tolerability and side effects of intake of high-dose and low-dose tart cherry juice OUTLINE: Tart cherry juice in both arms must begin ≤ 7 days from start of taxane therapy. During treatment, each participant in the high-dose group will consume 1 oz of tart cherry juice twice per day for up to 14 weeks (maximum cumulative volume of 196 oz). Each participant in the low-dose group will consume ¼ oz of tart cherry juice twice per day for up to 14 weeks (maximum cumulative volume of 49 oz). Participants will have follow-up visits at the conclusion of chemotherapy and at 12 months.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 86
Est. completion date June 2027
Est. primary completion date February 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologically confirmed invasive breast or ovarian cancer (Stage I, II, III, or IV) as per AJCC 8th Edition, 2018 Staging Criteria. - Must be planning to receive paclitaxel weekly for 12 weeks (12 weeks total) as part of neoadjuvant, adjuvant, or metastatic cancer treatment. - Concurrent biologic therapy (e.g., trastuzumab and pertuzumab) is allowed. - Currently receiving hormone therapy, bisphosphonates, denosumab or LHRH-agonists is allowed. - Concurrent use of immune checkpoint inhibitor therapy is allowed. - (Neo)adjuvant chemotherapy with doxorubicin and cyclophosphamide is allowed. - Concurrent use of carboplatin with weekly paclitaxel in the study is allowed. - May participate concurrently in other cancer trials. - Must be able to complete questionnaires in English or Spanish. - Age = 18 years old at the time of consent. - ECOG performance status of 0 - 1 (Karnofsky scale = 70%, see Appendix). - Ability to understand and the willingness to sign a written informed consent document. - Individuals of child-bearing potential must agree to use birth control (e.g., hormonal or barrier method; abstinence, an intrauterine device) prior - to study entry, for the duration of study participation (including dose interruptions), and for 3 months after the last dose of tart cherry juice supplement; or be surgically sterilized (e.g., hysterectomy or tubal ligation). - Patients with known human immunodeficiency virus (HIV) are allowed in the study, but HIV-positive patients must have: - A stable regimen of highly active anti-retroviral therapy (HAART) - No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections - A CD4 count above 250 cells/µL and an undetectable HIV viral load on standard PCR-based tests within the last year. - Stated willingness to not drink any additional tart cherry or any cherry juice while on the study. - Ability and willingness to adhere to the study visit schedule and other protocol requirements Exclusion Criteria: - Have received any prior therapy with taxanes, vinca alkaloids, eribulin, ixabepilone, or platinum. Doxorubicin is allowed (= 2 week washout period required). - Active or history of peripheral neuropathy, or any chronic diseases associated with peripheral neuropathy such as diabetes mellitus, alcohol use disorder, or systemic lupus erythematosus. - Currently taking anticoagulant medication. - Currently taking Vitamin E, glutamine, alpha lipoic acid, gabapentin, nortriptyline, amitriptyline or duloxetine. If a patient is taking any of these supplements/medications, they must agree to stop at the time of registration. Multivitamins containing Vitamin E are allowed, however Vitamin E > 1,000 international units (IU) must be discontinued at the time of registration. - Patients may not use cold therapy gloves for chemotherapy induced neuropathy. - Known allergy to cherries. - Inability to swallow liquid. - Pregnant or breastfeeding individuals (lactating individuals must agree not to breast feed while taking study juice supplementation). - Any condition that would prohibit the understanding or rendering of informed consent. - Any condition that in the opinion of the investigator would interfere with safety or compliance while on trial.

Study Design


Related Conditions & MeSH terms

  • Breast Cancer
  • Breast Cancer Invasive
  • Breast Cancer Stage I
  • Breast Cancer Stage II
  • Breast Cancer Stage IIA
  • Breast Cancer Stage IIB
  • Breast Cancer Stage III
  • Breast Cancer Stage IIIA
  • Breast Cancer Stage IIIB
  • Breast Cancer Stage IIIc
  • Breast Cancer Stage IV
  • Breast Carcinoma
  • Breast Neoplasm
  • Breast Neoplasms
  • Cancer of Ovary
  • Cancer, Breast
  • Carcinoma
  • Carcinoma, Ovarian Epithelial
  • Invasive Breast Cancer
  • Malignant Breast Neoplasm
  • Malignant Tumor of Breast
  • Mammary Cancer
  • Mammary Carcinoma
  • Neoplasms
  • Ovarian Cancer
  • Ovarian Cancer Stage III
  • Ovarian Cancer Stage IIIb
  • Ovarian Cancer Stage IIIC
  • Ovarian Cancer Stage IV
  • Ovarian Neoplasms
  • Ovary Cancer
  • Ovary Neoplasm
  • Tumors, Breast

Intervention

Drug:
Tart Cherry Juice
Given PO

Locations

Country Name City State
United States University of California Davis Comprehensive Cancer Center Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
Eve Rodler

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of tart cherry juice supplementation in the prevention of paclitaxel-induced peripheral neuropathy (PIPN) in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy. Number of participants between study arms experiencing PIPN using the 11-item peripheral neuropathy component of the Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane) survey. Up to 1 year.
Secondary Compare the effectiveness of high- dose and low-dose tart cherry juice supplement in reducing the severity of PIPN in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy. Assessment of the severity of PIPN using the Functional Assessment of Cancer Therapy-Taxane (FACT-Taxane) neuropathy subscale survey and National Cancer Institute Common Terminology Criteria for Adverse Events version 5 (NCI CTCAE v.5) physician assessment. Up to 1 year.
Secondary Assess the impact of tart cherry juice on dose delivery of taxane chemotherapy. Number of participants between arms experiencing dose reductions, delays, or discontinuations. Up to 1 year.
Secondary Tolerability of daily intake of high-dose and low-dose tart cherry juice. Number of participants between study arms =90% compliant with daily consumption of tart cherry juice. Up to 1 year.
Secondary Safety profile of daily intake of high-dose and low-dose tart cherry juice. Number of participants between study arms with adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5). Up to 1 year.
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A